Viral Vector News and Research

RSS

Viral Vector is a type of virus used in cancer therapy. The virus is changed in the laboratory and cannot cause disease. Viral vectors may produce tumor antigens (proteins found on a tumor cell) to stimulate an antitumor immune response in the body. Viral vectors may also be used to carry genes that can change cancer cells back to normal cells.

Protein-based nanoparticle vaccines for protection against SARS-CoV-2

A recent review article discusses recent advances in protein-based nanoparticle vaccines against SARS-CoV-2.

22 Dec 2021

Effect of T cell reactivity in COVID-19 infection and vaccination

Researchers recently developed an immunodiagnostic T cell assay to classify T cell immune responses of the subjects based on their coronavirus disease 2019 infection and vaccination history.

21 Dec 2021

Risk of Guillain-Barré syndrome decreases after COVID-19 vaccination

A new study suggests that low GBS incidence in vaccinated patients compared to non-vaccinated people should encourage the active propagation of vaccination against SARS-CoV-2.

15 Dec 2021

Booster vaccination can reduce breakthrough infection risk in HIV patients

New study reveals that people with HIV are at a high risk of breakthrough COVID-19 infection in comparison to people without HIV, and that booster vaccinations can be protective for those living with HIV.

9 Dec 2021

Immunogenicity and safety of COVID-19 subunit vaccine Nanocovax in animal models

Researchers have developed Nanocovax, a COVID-19 subunit vaccine based on recombinant protein technology to produce the extracellular (soluble) portion of the S protein of SARS-CoV-2.

9 Dec 2021

Study reveals how a protein in the blood is attracted to key component of Adenovirus-based vaccines

A collaborative team from the School of Medicine at the University of Cardiff, Wales and a range of US institutions used the UK's national synchrotron, Diamond Light Source, to help reveal the details of how a protein in the blood is attracted to a key component of Adenovirus based vaccines.

8 Dec 2021

SARS-CoV-2 vaccine based on vesicular stomatitis virus exhibits high neutralizing efficacy against variants

Scientists have tested the efficacy of BriLife®-vaccinated human sera in neutralizing more infectious and probably more virulent SARS-CoV-2 variants.

26 Nov 2021

Real-world effectiveness and safety of COVID-19 vaccines

A new study published in Infectious Diseases of Poverty aimed to systematically evaluate the effectiveness and safety of the COVID-19 vaccines in the real world as well as establish a reliable evidence-based basis to determine the actual protective effect of the COVID-19 vaccines, especially considering the new waves of infection brought about by the variants.

18 Nov 2021

Study shows neutralizing capacity of monoclonal antibodies against SARS-CoV-2 variants of concern

Canadian public health researchers recently published a study in the journal Antiviral Research wherein they described generating a panel of murine hybridomas recognizing SARS-CoV-2 spike protein or nucleoprotein, capable of neutralizing the SARS-CoV-2 variants of concern, proving their therapeutic potential.

17 Nov 2021

COVID-19 vaccination and deaths amongst US veterans

A new study studies the vaccine effectiveness and death in the Veterans Health Administration.

8 Nov 2021

Study finds benefits of COVID vaccination in pregnancy outweighs risks

A new preprint explores the efficacy of vaccination against infection with SARS-CoV-2 in pregnancy.

4 Nov 2021

COVID-19 vaccine-elicited immune responses in myeloma patients

Researchers collaborated to address these evidence gaps by initiating a web-based prospective study of adults diagnosed with multiple myeloma to determine the immune response to the first and second dose of the COVID-19 vaccine.

27 Oct 2021

COVID-19 vaccination side effects in the USA

A new study described and compared self-reported side effects of three different COVID-19 vaccines administered between March 19 and July 15, 2021, in the United States.

20 Oct 2021

Researchers identify common side effects of three COVID-19 vaccines

COVID-19 vaccines remain the best tool in the pandemic toolbox against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). But they are not perfect; reports have surfaced of mild to severe side effects after vaccination. A new study from researchers in the Lampe & Company GmbH & Co. KG compared the severity of adverse events from each coronavirus vaccine.

17 Oct 2021

Study finds relatively low rate of COVID-19 infection following full vaccination in North Carolina

A recent study seeks to investigate the characteristics of individuals with breakthrough infections post-vaccination in North Carolina, USA.

14 Oct 2021

Study finds common adverse events between Flu and COVID-19 vaccines

A study compared the top 10 common adverse events of COVID-19 vaccines and flu vaccine’s adverse effects.

28 Sep 2021

Oxford COVID vaccine technology has the potential to revolutionize cancer treatment

Scientists from the University of Oxford and the Ludwig Institute for Cancer Research are building on the success of the Oxford-AstraZeneca vaccine against SARS-CoV-2 to develop a vaccine to treat cancer.

21 Sep 2021

Three US COVID-19 vaccines provide substantial protection against hospitalization

A new study reports that a head-to-head comparison of the efficacy of the three vaccines used in the USA indicates substantial protection against hospitalization with COVID-19 following vaccination with any of these vaccines.

21 Sep 2021

Scientists develop a novel and potent SARS-CoV-2 RBD-homodimer vaccine

A recent report published in the journal Cell Discovery has described the immunogenicity and protective efficacy of a novel coronavirus disease 2019 (COVID-19) subunit vaccine candidate. The vaccine induces robust immune responses in rodents and non-human primates and protects the animals against severe disease.

12 Sep 2021

First rat model recapitulates all disabling alterations experienced by patients with Morquio A disease

A research team from the Universitat Autònoma de Barcelona has generated the first rat model recapitulating all disabling alterations experienced by patients with Mucopolysaccharidosis type IVA, also known as Morquio A disease.